Premium
A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma
Author(s) -
Jones Ellen L.,
Samulski Thaddeus V.,
Dewhirst Mark W.,
AlvarezSecord Angeles,
Berchuck Andrew,
ClarkePearson Daniel,
Havrilesky Laura J.,
Soper John,
Prosnitz Leonard R.
Publication year - 2003
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11475
Subject(s) - medicine , cervical cancer , radiation therapy , chemotherapy , pelvis , carcinoma , hyperthermia , chemoradiotherapy , cisplatin , nasopharyngeal carcinoma , cervical carcinoma , surgery , oncology , phases of clinical research , radiology , cancer
BACKGROUND Five randomized studies have demonstrated a benefit derived from adding cisplatin (CDDP)‐based chemotherapy to radiotherapy (RT) for treatment of cervical carcinoma. The Dutch Phase III pelvic tumor trial demonstrated a survival and local control benefit due to the addition of hyperthermia (HT) to RT. The authors evaluated response and toxicity in patients with locally advanced cervical carcinoma (LACC) who were treated with concurrent weekly CDDP, HT, and RT (whole pelvis [ n = 7] and whole pelvis and paraaortic nodes [ n = 5]). METHODS From August 1998 through December 2000, 12 patients with LACC or locally recurrent cervical carcinoma (LRCC) following hysterectomy were enrolled on a pilot study combining weekly CDDP, HT, and RT. RESULTS Ten patients were treated at initial diagnosis. All achieved clinical complete response and durable local control. Two of the 10 experienced recurrence outside the pelvis; 1 of these patients had pulmonary metastasis, and the other had isolated paraaortic nodal involvement. Two patients treated for LRCC experienced local and systemic progression and died of disease within 6 months. CONCLUSIONS In this small series, trimodality therapy resulted in an excellent clinical response and was well tolerated. The addition of HT to chemoradiotherapy represents a promising new strategy that warrants multiinstitutional collaborative efforts to confirm its efficacy. Cancer 2003;98:277–82. © 2003 American Cancer Society. DOI 10.1002/cncr.11475